By Vincent Couey, RxGrab founder. Reviewed by Vincent Wesley Couey. Updated .
For years, the most effective GLP-1 weight-loss drugs came only as weekly injections. Foundayo changes that: it is the first GLP-1 you swallow, approved specifically for weight loss, and Eli Lilly priced it to undercut the injectables. Here is what it actually costs, how to get it, and the honest tradeoff against the injectable options covered in our Zepbound vs Wegovy guide.
Foundayo is sold through Eli Lilly's LillyDirect online pharmacy with free home delivery. The two headline prices:
| Path | Monthly Cost | Notes |
|---|---|---|
| With commercial insurance | ~$25/mo | Via LillyDirect, if your plan covers it |
| Self-pay (no insurance) | $149/mo | Via LillyDirect, free home delivery |
| Brand injectable GLP-1s (for comparison) | $300-$450/mo | Zepbound / Wegovy self-pay |
The $149 self-pay price is the headline. It is less than half the self-pay cost of the injectable brand GLP-1s, which is a genuine shift: for the first time, a brand-name GLP-1 for weight loss is available for cash under $150 a month. Higher dose tiers and any Medicare coverage may differ, so confirm the exact price for your dose at LillyDirect, and remember this is a brand-new 2026 product whose pricing and availability are still settling.
For the first time, a brand-name GLP-1 for weight loss is available for cash under $150 a month.THE FOUNDAYO SHIFT
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist. The FDA approved it on April 1, 2026, for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and more physical activity. Two things make it notable:
Because orforglipron is a small-molecule drug rather than a peptide, it is easier to manufacture at scale, which is part of why Lilly can price and supply it differently from semaglutide-based options.
Cost and convenience favor Foundayo. Maximum weight loss favors the injectables. Here is the honest side-by-side:
| Drug | Form | Avg weight loss (trials) | Self-pay cost | Convenience |
|---|---|---|---|---|
| Foundayo (orforglipron) | Daily pill | ~11.2% (ATTAIN-1) | $149/mo | Anytime, no food/water rules |
| Zepbound (tirzepatide) | Weekly injection | ~20% (SURMOUNT-5) | $299-$449/mo | Weekly self-injection |
| Wegovy (semaglutide) | Weekly injection | ~14% (SURMOUNT-5) | ~$350/mo | Weekly self-injection |
Weight-loss figures are from separate trials (orforglipron's ATTAIN-1; tirzepatide and semaglutide from SURMOUNT-5), not a single head-to-head study, so treat them as approximate ranges rather than an exact ranking. Sources: Eli Lilly, FDA approval, AJMC, and the published trial data.
The decision comes down to what you weigh most heavily:
You need a prescription. As of 2026 the main route is LillyDirect, Lilly's online pharmacy, which accepts prescriptions and ships to your home, with broader availability through U.S. retail pharmacies and telehealth providers rolling out after launch. The practical path: talk to your doctor or a telehealth prescriber about whether orforglipron fits your situation, then fill through LillyDirect for the $25 insured or $149 self-pay pricing. For the semaglutide and tirzepatide options, see our Ozempic cost guide and Mounjaro cost guide.
Through LillyDirect with free home delivery, Foundayo costs about $25/month with commercial insurance and $149/month self-pay. That $149 self-pay price is far below brand injectable GLP-1s at roughly $300 to $450/month. Confirm current pricing, dose tiers, and any Medicare coverage at LillyDirect, and note this is a new 2026 product so pricing may change.
Yes. The FDA approved Foundayo (orforglipron) on April 1, 2026, for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and exercise. It is the first oral GLP-1 weight-loss pill that can be taken any time of day without food or water restrictions, and became available via LillyDirect immediately, with retail and telehealth availability following.
Not quite, and that is the core tradeoff. In its ATTAIN-1 trial (about 3,100 adults over 72 weeks), orforglipron produced about 11.2% average weight loss, with more than half losing at least 10% of body weight. That is meaningful but below the strongest injectables: in separate trials injectable tirzepatide (Zepbound) reached about 20% and injectable semaglutide (Wegovy) about 14%. Foundayo trades some maximum weight loss for the convenience of a daily pill and a much lower price.
Both are oral GLP-1 pills, but Foundayo is easier to take. Foundayo (orforglipron) can be taken any time of day with or without food and water. Oral Wegovy (semaglutide) must be taken in the morning on an empty stomach with no more than four ounces of water, and you wait about 30 minutes before eating, drinking, or taking other medicine. Foundayo is also a small-molecule pill, part of why Lilly can produce and price it differently from peptide-based semaglutide.
You need a prescription. The primary route in 2026 is LillyDirect, Lilly's online pharmacy, which accepts prescriptions and ships to your home, followed by retail pharmacies and telehealth. Talk to your doctor or a telehealth prescriber about whether orforglipron is appropriate, then fill through LillyDirect for the $25 insured or $149 self-pay pricing.
We track direct-pay pricing, new approvals, and coverage changes for Foundayo, Zepbound, Wegovy, and the rest.